Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P8MB
|
|||
| Former ID |
DIB002328
|
|||
| Drug Name |
AIGIV
|
|||
| Synonyms |
Anthrax immune globulin therapy (intravenous); Anthrax immune globulin therapy (intravenous), Emergent
Click to Show/Hide
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z; ICD-10: G63, G63.2] | Phase 1/2 | [1] | |
| Company |
Adma biologics; emergent biosolutions
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacillus anthracis Protective antigen (Anthrax PA) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00845650) Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV). U.S. National Institutes of Health. | |||
| REF 2 | Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.